Loading organizations...
October Capital operates as a family investment vehicle, specializing in providing seed money and expansion capital to early-stage companies. The firm actively seeks investment opportunities within businesses poised to introduce transformational change to existing markets or those developing entirely new market segments. Their approach is characterized by identifying novel, entrepreneurial ventures with high growth potential, leveraging deep expertise in strategic leadership and technologically advanced applications.
The firm was founded in October 1999 by Ron and Lance LeMay, who combined their backgrounds to establish this investment entity. Their founding insight centered on the belief that significant value can be generated by identifying and nurturing companies that demonstrate innovative approaches and show promise for substantial market disruption or creation. This foundation allows them to focus on ventures where their operational experience can contribute meaningfully beyond mere capital provision.
October Capital primarily serves entrepreneurial start-ups across diverse industry segments, offering crucial early-stage and expansion funding. The company’s overarching vision is to position itself at the nexus of innovation, where promising ideas converge with market possibility. They aim to support and foster the launch of groundbreaking concepts, driving forward-looking growth and impactful market development.
October Capital has 5 tracked investments across 5 companies. The latest tracked deal is $14.0M Series A in Saimei Measurement and Control in September 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 11, 2025 | Saimei Measurement and Control | $14.0M Series A | October Capital | Yida Capital, Yuanhe Houwang |
| Nov 1, 2023 | Shengteng Semiconductor | $13.7M Series B | — | Hefei Guoxin Capital, Qingdao Huazishengtong, Shenzhen Southern Equity |
| Jun 19, 2023 | Anhui YOFC Advanced Semiconductor | $531.7M Series A | — | CCB Trust |
| Aug 31, 2022 | Biointron | $72.5M Series B | — | CS Capital, Gaorong Capital |
| Oct 13, 2021 | Laviana Pharma | $77.5M Series C | — | Huayi Capital |